United States - English - myHealthbox

ecolab -

United States - English - myHealthbox

ecolab -

United States - English - myHealthbox

ecolab -

Australia - English - Department of Health (Therapeutic Goods Administration)

colgate-palmolive pty ltd -

Singapore - English - HSA (Health Sciences Authority)

abbott medical (singapore), pte. ltd. - cardiovascular - indicated for improving coronary luminal Ø in patients with : • symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. • experiencing ami who present within 12 hrs of symptom onset. • concomitant diabetes, acute coronary syndrome, dual vessel lesions (two lesions in 2 different epicardial vessels), lesions residing within small coronary vessels; lesions where treatment results in jailing of side branches (lesions with a side branch <2mm in Ø or an ostial stenosis <50%); for the treatment of patients (age ≥65), and for treatment of men & women. • in-stent restenosis in coronary artery lesions; cto coronary artery lesions (defined as coronary artery lesions with timi flow 0 and lasting longer than 3 months); and coronary artery bifurcation lesions. in all cases, the treated lesion length should be less than the nominal stent length (8, 12, 15, 18, 23, 28, 33, or 38mm) with a reference vessel Ø of ≥2.00 and ≤4.25 mm.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

sonoray pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

sonoray pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

sonoray pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

sonoray pty ltd -